Rexahn Pharmaceuticals (RNN) has been under a strong bear grip, hence the stock is down -1.94% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.5% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.43% in the last 1 week, and is up 1.35% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 1.43% and the 50-Day Moving Average is 3.18%. Rexahn Pharmaceuticals, Inc. has dropped 12.5% during the last 3-month period . Year-to-Date the stock performance stands at -27.69%.
Rexahn Pharmaceuticals (NYSEMKT:RNN): stock turned positive on Friday. Though the stock opened at $0.2599, the bulls momentum made the stock top out at $0.2745 level for the day. The stock recorded a low of $0.2575 and closed the trading day at $0.2625, in the green by 1.00%. The total traded volume for the day was 978,788. The stock had closed at $0.2599 in the previous days trading.
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active development: Archexin, a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance; RX-3117, a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including colon, lung and pancreatic cancer, and Supinoxin (RX-5902), a small molecule that inhibits the phosphorylation of p68, which is expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation or tumor growth of cancer cells. The Company also has two drug candidates in pre-clinical development: Archexin-Nano and RX-21101.